Tivic Featured in ABC News Report: “New Bioelectronic Technologies Could Signal the Future of Medicine”

Growing recognition of Bioelectronic Medicine as an important new therapeutic category

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase healthtech company focused on bioelectronic medicine, was one of two companies featured in the ABC News story “New Bioelectronic Technologies Could Signal the Future of Medicine.”

Will Carr reported on the new, cutting-edge bioelectronic technologies that are being used today to help individuals manage chronic conditions ranging from conditions such as sinus pain and congestion to rheumatoid arthritis and Parkinson’s disease.

Tivic Health is one of two commercial companies highlighted in the broadcast and the company’s sinus care product, ClearUP® Sinus Pain Relief, is the only product featured that is commercially available and does not require surgical intervention.

In November 2021, the company raised $17.2 Million in its initial public offering to execute its growth strategy through:

1. Fueling sales of their ClearUP product through expansion of advertising and social media engagement
2. Advancement of the company’s Gen2 product
3. Expansion into new applications of its bioelectronic platform for non-invasive peripheral nerve stimulation (nPNS).

In December 2021, Tivic Health was recognized by Fast Company as part of the publication’s inaugural “Next Big Things in Tech 2021.” Also in December 2021, the company announced its partnership with Mindgruve, a leading consumer marketing firm as the digital agency of record.

In January 2022, Tivic Health announced its partnership with a leading hospital and research system testing an extension of the company’s bioelectronic platform as a new alternative to opioids for post-operative care following sinus surgeries.

“We continue to see growing interest in bioelectronic therapies as a means to fight disease and improve health,” said Jennifer Ernst, CEO of Tivic Health. “We are excited to be executing on the plans laid out in our IPO and seeing the broader traction as consumers and healthcare professionals recognize the tremendous opportunities in bioelectronic medicine.”

About Tivic Health Systems, Inc.

Tivic Health Systems, Inc. is a commercial-phase healthtech company delivering non-invasive bioelectronic treatments that provide consumers choice in the treatment of inflammation and related conditions. For more information visit https://tivichealth.com. @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Additional information concerning Tivic Health and its business, including a discussion of factors that could materially affect the company operating results, are contained in the company’s Registration Statement on Form S-1 (and amendments thereto) under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005538/en/